SRC
Overview
SRC encodes a non-receptor tyrosine kinase and is the prototypical member of the SRC-family kinase (SFK) group. SRC and related kinases (LYN, YES1) transduce mitogenic and survival signals downstream of growth factor receptors, integrins, and cell-adhesion molecules. In oral squamous cell carcinoma (OSCC), SRC-family kinases are collectively amplified and overexpressed as a group, making them potential therapeutic targets.
Alterations observed in the corpus
- SRC and SRC-family kinases LYN and YES1 are collectively altered (copy gain with high expression) in 29% (10/35) of oral squamous cell carcinoma (OSCC) tumors PMID:23619168
- Identified as a univariate survival hit in MSS mCRC but did not retain significance in multivariate analysis alongside APC, BRAF, KRAS, and NRAS. PMID:29316426
Cancer types (linked)
- OSCC: SRC-family kinases (SRC, LYN, YES1) collectively altered in 29% of OSCC; part of the mitogenic signaling pathway altered in 63% of tumors PMID:23619168
Co-occurrence and mutual exclusivity
- SRC copy gain co-occurs with PIK3CA activation, EGFR amplification, CCND1 amplification, and other mitogenic pathway alterations in OSCC PMID:23619168
Therapeutic relevance
- SRC-family kinase inhibitors (e.g., dasatinib) are a potential therapeutic strategy in SRC-altered OSCC tumors; no clinical trial data reported in this cohort.
Open questions
- Individual frequencies for SRC vs. LYN vs. YES1 alterations are not separated in this cohort; the relative contribution of each family member to OSCC oncogenesis requires further study.
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:29316426
This page was processed by entity-page-writer on 2026-05-15.